首页> 美国卫生研究院文献>Diabetology Metabolic Syndrome >Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study
【2h】

Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study

机译:己酮可可碱对2型糖尿病患者蛋白尿和血糖控制的影响:一项前瞻性随机双盲多中心研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPentoxifylline is a methylxanthine derivative with significant anti-inflammatory, anti-fibrotic, and anti-proliferative properties. Studies have shown that pentoxifylline may have renoprotective effects in patients with diabetic nephropathy. However, most of these studies were limited by small sample sizes. Therefore, we investigated whether pentoxifylline could reduce proteinuria in patients with diabetic nephropathy and residual proteinuria who received an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB). We also studied the effects of pentoxifylline on glycemic control, insulin resistance, and inflammatory parameters.
机译:背景己酮可可碱是具有显着的抗炎,抗纤维化和抗增殖特性的甲基黄嘌呤衍生物。研究表明,己酮可可碱对糖尿病肾病患者可能具有肾脏保护作用。但是,这些研究大多数都受到样本量较小的限制。因此,我们研究了己酮可可碱是否可以降低接受血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体阻滞剂(ARB)的糖尿病肾病和残余蛋白尿患者的蛋白尿。我们还研究了己酮可可碱对血糖控制,胰岛素抵抗和炎症参数的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号